NCT03034304 2025-07-24
A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors
HRYZ Biotech Co.
Phase 1 Terminated
HRYZ Biotech Co.
BeBetter Med Inc
Eli Lilly and Company
Eli Lilly and Company
Gilead Sciences
Merck Sharp & Dohme LLC
Alaunos Therapeutics